Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2005-08-02
2005-08-02
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S320100, C435S069100, C435S455000, C435S325000, C536S023100, C536S023720, C536S024100
Reexamination Certificate
active
06924144
ABSTRACT:
Lentiviral vectors modified at the 5′ LTR or both the 5′ and 3′ LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production.
REFERENCES:
patent: 5583022 (1996-12-01), Heidmann et al.
patent: 5614404 (1997-03-01), Mazzara et al.
patent: 5650309 (1997-07-01), Wong-Staal et al.
patent: 5665577 (1997-09-01), Sodroski et al.
patent: 5681746 (1997-10-01), Bodner et al.
patent: 5686279 (1997-11-01), Finer et al.
patent: 5693508 (1997-12-01), Chang
patent: 5716613 (1998-02-01), Guber et al.
patent: 5716826 (1998-02-01), Gruber et al.
patent: 5739118 (1998-04-01), Carrano et al.
patent: 5747307 (1998-05-01), Lever et al.
patent: 5750383 (1998-05-01), Blissard et al.
patent: 5994136 (1999-11-01), Naldini et al.
patent: 6013516 (2000-01-01), Verma et al.
patent: 6165782 (2000-12-01), Naldini et al.
patent: 6207455 (2001-03-01), Chang
patent: 6312682 (2001-11-01), Kingsman et al.
patent: 6365150 (2002-04-01), Leboulch et al.
patent: 0 759 471 (1997-02-01), None
patent: WO 95/32300 (1995-11-01), None
patent: WO 97/07225 (1997-02-01), None
patent: WO 97/20052 (1997-06-01), None
patent: WO 98/12314 (1998-03-01), None
patent: WO 98/17816 (1998-04-01), None
patent: WO 99/04026 (1999-01-01), None
Dull et al., J. Virol., Nov., 1998, vol. 72, No. 11, pp. 8463-8471.
Srinivasakumar et al., J. Virol., Aug. 1997, vol. 71, No. 8, pp. 5841-5848.
Xu et al., Molecular Therapy, Jan. 2001, vol. 3, No. 1, pp. 97-104.
Miyoshi, H., et al., “Development of a Self-Inactivating Lentivius Vector”, Journal of Virology, American Society for Microbiology, Oct. 1998, vol. 72, No. 10, pp. 8150-8157, XP-000886313.
Robinson, D., et al., “Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat”, Gene Therapy, Jun. 1995, vol. 2, No. 4, pp. 269-278, XP 000604985.
Shinya, E., et al., A Safe HIV Vectors Packaging System Using the U3 Deficient LTR, Gene Therapy Meeting, Sep. 21, 1994, p. 150, XP-002063696.
Berkhout et al., “Tat Transactivates the Human Immunodeficiency Virus Through a Nascent RNA Target,” Cell, 1989, vol. 59: 273-282.
Blomer et al., “Highly Efficient and Sustained Gene Transfer in Adult Neurons with a Lentivirus Vector,” Jnl. of Virology, Sep. 1997, vol. 71(9): 6641-6649.
A. Bukovsky et al., “Interaction of Human Immunodeficiency Virus-Derived Vectors with Wild-Type Virus in Transduced Cells,” Jnl. of Virology, Aug. 1999, vol. 73(8): 7087-7092.
N. Ferry et al., “Liver-Directed Gene Transfer Vectors,” Human Gene Therapy, Sep. 1998, vol. 9: 1975-1981.
T. Kafri et al., “Sustained Expression of Genes Delivered Directly Into Liver and Muscle by Lentiviral Vectors,” Nature Genetics, Nov. 1997, vol. 17: 314-317.
Lisziewicz et al., “Inhibitors of Human Immunodeficiency Virus Type I Replication By Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS,” Proc. Natl. Acad. Sci. USA, 1993, vol. 90: 8000-8004.
L. Naldini et al., “Efficient Transfer, Integration, and Sustained Long-Term Expression of the Transgene in Adult Rat Brains Injected with a Lentiviral Vector,” Proc. Natl. Acad. Sci. USA, Oct. 1996, vol. 93: 11382-11388.
L. Naldini et al., “In Vivo Gene Delivery and Stable Transduction of Nondiving Cells by a Lentiviral Vector,” Science, Apr. 1996, vol. 272: 263-267.
L. Naldini et al., “Lentiviruses as Gene Transfer Agents for Delivery to Non-Dividing Cells,” Curr. Opin. Biotech., 1998, 9: 457-63.
D. Ory et al., “A Stable Human-Derived Packaging Cell Line for Production of High Titer Retrovirus/Vesicular Stomatitias Virus G Pseudotypes,” Proc. Natl. Acad. Sci. USA, Oct. 1996, vol. 93:11400-11406.
R. Schneider et al., “Inactivation of the Human Immunodeficiency Virus Type I Inhibitory Elements Allows Rev-Independent Expression of Gag and Gag/Protease and Particle Formation,” Jnl. of Virology, Jul. 1997, vol. 71(7): 4892-4903.
M.A. Zern et al., “Hepatic Drug Delivery and Gene Therapy,” Hepatology, 1997, 25(2): 484-491.
R. Zufferey et al., “Multiply Attenuated Lentiviral Vector Achieves Efficient Gene Delivery In Vivo,” Nature Biotechnology, Sep. 1997, vol. 15: 871-875.
R. Zufferey et al., “Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery,” Jnl. of Virology, Dec. 1998, vol. 72(12): 9873-9880.
JM Coffin, Fundamental Virology, 1996, 3rdEdition (Fields et al., eds), Chapter 26, “Retroviridar. The Viruses and Their Replication,” pp. 763-843, Lipincott-Raven Publishers, Philadelphia, PA.
Elder et al., “Feline Immunodeficiency Virus as a Model for Development of Molecular Approaches to Intervention Strategies Against Lentivirus Infections,” Adv. Virus Res., 1995, vol. 45: pp. 225-247.
Dull Thomas
Farson Deborah A.
Naldini Luigi
Witt Rochelle
Cell Genesys Inc.
Gates & Cooper LLP
Guzo David
Winkelman Jeffrey W.
LandOfFree
Method and means for producing high titer, safe, recombinant... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and means for producing high titer, safe, recombinant..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and means for producing high titer, safe, recombinant... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3523412